Erytech Pharma SA

Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
  • TickerERYP
  • ISINFR0011471135
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Charles Lepetitpas ...
  • Christophe Chaput
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/12/2019

FFP is due to report its NAV at end-2018 on 18 March. We estimate this at € 148 per share, down 5% over 2018. Since the start of 2019, we estimate the rebound at 13% to € 167 per share. Buy recommendation maintained to benefit from dual leverage on the valuation: growth in NAV (the track record is excellent) and narrowing of the discount (historically high level of 43%). Target price lowered to € 131 vs € 136 previously. - ...

Anis Zgaya ...
  • Charles Lepetitpas
  • Christophe Chaput
  • François Maury
  • Georges Dieng
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 12/03/2019

...

Oussema Denguir ...
  • Pierre Corby

Erytec Pharma : € 134.4m in cash at end-2018

>2018 results - Yesterday evening, Erytech Pharma reported its figures for FY2018. Revenues rose to € 4.4m (vs € 3.3m) due to the increase in the research tax credit. The operating loss deepened to -€ 43.6m (vs -€ 30.9m in 2017) following the increase of: i/ 31% in R&D costs to € 33.4m, which underscored the acceleration in clinical businesses; and ii/ 66% in SG&A to € 14.6m, linked to the expansion of the US businesses. As such, the net loss deepened to -€ 38.2m (vs...

Oussema Denguir ...
  • Pierre Corby

Erytech Pharma : 134.4 M€ de cash à fin 2018

>Résultats 2018 - Erytech Pharma a publié hier soir ses chiffres au titre de l’exercice 2018 : les revenus progressent à 4.4 M€ (vs 3.3 M€) du fait de l’augmentation du CIR, la perte d’exploitation se creuse à -43.6 M€ (vs -30.9 M€ en 2017) sous l’effet de l’augmentation i/ des frais R&D de 31% à 33.4 M€ qui soulignent l’accélération des activités cliniques et ii/ des charges de structure de 66% à 14.6 M€ associés à l’expansion des activités américaines. La perte nett...

Anis Zgaya ...
  • Charles Lepetitpas
  • Christophe Chaput
  • François Maury
  • Georges Dieng
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 12/03/2019

...

Oussema Denguir ...
  • Pierre Corby

Erytec Pharma : € 134.4m in cash at end-2018

>2018 results - Yesterday evening, Erytech Pharma reported its figures for FY2018. Revenues rose to € 4.4m (vs € 3.3m) due to the increase in the research tax credit. The operating loss deepened to -€ 43.6m (vs -€ 30.9m in 2017) following the increase of: i/ 31% in R&D costs to € 33.4m, which underscored the acceleration in clinical businesses; and ii/ 66% in SG&A to € 14.6m, linked to the expansion of the US businesses. As such, the net loss deepened to -€ 38.2m (vs...

Oussema Denguir ...
  • Pierre Corby

Erytech Pharma : 134.4 M€ de cash à fin 2018

>Résultats 2018 - Erytech Pharma a publié hier soir ses chiffres au titre de l’exercice 2018 : les revenus progressent à 4.4 M€ (vs 3.3 M€) du fait de l’augmentation du CIR, la perte d’exploitation se creuse à -43.6 M€ (vs -30.9 M€ en 2017) sous l’effet de l’augmentation i/ des frais R&D de 31% à 33.4 M€ qui soulignent l’accélération des activités cliniques et ii/ des charges de structure de 66% à 14.6 M€ associés à l’expansion des activités américaines. La perte nett...

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Charles Lepetitpas ...
  • Christophe Chaput
  • Jean-François Granjon
  • Jeremy Garnier
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/12/2019

FFP is due to report its NAV at end-2018 on 18 March. We estimate this at € 148 per share, down 5% over 2018. Since the start of 2019, we estimate the rebound at 13% to € 167 per share. Buy recommendation maintained to benefit from dual leverage on the valuation: growth in NAV (the track record is excellent) and narrowing of the discount (historically high level of 43%). Target price lowered to € 131 vs € 136 previously. - ...

Emmanuel Matot ...
  • Jean-François Granjon
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 27/06/2018

...

Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 25/06/2018

...

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

ValuEngine Rating and Forecast Report for ERYP

Etude de l'AG du 27/06/2017

Concernant les diverses indemnités de départs convenues au bénéfice des dirigeants, bien que les montants maximum des indemnités soient en ligne avec le plafond de 12 mois de rémunération salariale (fixe + bonus annuel) fixé par Proxinvest, les motifs donnant droit au versement de celles-ci ne respectent pas la politique de Proxinvest qui en limite le versement à la seule hypothèse d’un départ contraint et lié à changement de contrôle. La résolution 17 relative à l’approbation des principes de détermination des éléments de rémunération des dirigeants pour l’exercice 2017 ne peut être soutenue...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch